'I look forward to accelerating technological innovation and strengthening our position in existing and emerging mobility segments,' Hazela said after the appointment
This agreement follows previous disclosures by Aurobindo Pharma about expanding its biologics manufacturing facilities and exploring contract manufacturing operations (CMO) for biologicals
Molbio Diagnostics became Goa's first startup to achieve unicorn status in September 2022 following a Rs 680 crore investment from Temasek and MOPE, plans to launch the IPO in November
In his new role, Mandeep Singh Kumar will be responsible for overseeing sales, marketing, and commercial operations for Medtronic's business in India
Varanasi faces challenges managing the influx of pilgrims and tourists, particularly regarding safety and accessibility in crowded areas
Mumbai and Delhi witness fastest growth in demand this year at 35% and 40%, respectively
30% of the Group's India production is exported
Strategic collaborations played a crucial role in AstraZeneca's achievements, particularly in enhancing diagnostic capabilities and treatment outcomes
Eyes acquisitions to broaden medical tech reach
The increase in PAT is attributed to expansion into the new markets, product launches and stable pricing
SUVs set to reach 45% of used car market soon
A compact, budget-friendly electric car from a major Indian manufacturer, could be the tipping point for widespread EV adoption
In Q4, the business-to-consumers (B2C) revenues grew by approximately 20 per cent Y-o-Y, and revenues from the Mumbai market also saw 20 per cent growth
The tyre maker remains optimistic about the tyre demand outlook, driven by robust infrastructure spending and buoyant economic activities
On a sequential basis, the company exhibited a 13.2 per cent increase in revenue; however, the PAT declined by 30.96 per cent
The increasing incidence of skin diseases and the growing awareness about these conditions among the Indian populace have been pivotal in driving the dermatology market's expansion
Crude prices, which hovered around $88 to 90 over the past three months, represent a 6 to 8 per cent increase from the previous quarter, adding further strain on manufacturers' margins
JB Pharma plans to maintain its presence in cardiology, focusing on hypertension, heart failure, and lipid-lowering treatments
For the full year of FY24, JB Pharma posted an 11 per cent Y-o-Y increase in revenue and a 35 per cent increase in PAT, reaching Rs 3,484 crore and Rs 553 crore respectively
The collaboration leverages SII's manufacturing and distribution strength with IntegriMedical's innovative technology